Healthium Medtech announced the launch of Trushield NXT surgical wound dressing, adding to its portfolio of patented products in the wound care and infection prevention segments. In addition to wound care, Healthium’s current product portfolio focuses on advanced surgery, urology and arthroscopy products covering 52,000 stock-keeping units.

Trushield NXT combines the advantages of a 3D hydrocellular substrate and patented infection prevention technology to offer a complete wound care system that provides 360-degree wound protection. It provides exudate and moisture management while remaining waterproof. Its patented technology continuously inhibits pathogen growth with a unique non-leaching, non-depleting kill mechanism. It has patents in the U.S, Europe and India.

The advanced wound care market is expected to grow at a CAGR of 8.8%. Dominated by traditional wound dressing such as cotton gauze, the Advanced wound dressing category has lagged in penetration because of the high pricing of products and limited availability. Trushield NXT is non-adherent (does not stick to the wound and can be easily removed) and waterproof with exudate management ability when compared to traditional wound dressing and reduces the need to repeatedly change dressings, thereby reducing costs.

Speaking on the new product launch Anish Bafna, CEO and MD, Healthium Medtech, said, “We are excited to add Trushield NXT to strengthen our wound care and post-surgical care portfolio. Aligned to our vision “Access to precision Medtech for every patient, globally”, Trushield NXT is manufactured to high-quality standards at our US FDA registered plant. With our sales network reaching 90% of districts in India with secondary healthcare facilities catering to 40,000 surgeons across 18000 hospitals, we look to offering wider choices to our customers and delivering better standards in patient care, with innovative and quality products.”